Bharat Biotech has been geared up to address the shortage of vaccines released in India. According to the company’s joint managing director Suchitra Ela, Bharat Biotech has announced on Thursday that it will manufacture additional doses of covaxine at its rabies vaccine facility in Gujarat. It is expected to gain momentum in the next four months. This will increase the Kovid vaccine capacity by 17 million doses in a month.
The Hyderabad-based company has decided to use its Chiron Behring vaccine facility, which it acquired from GlaxoSmithKline in 2019, to manufacture rabies vaccines. This will help accelerate the manufacture of the Kovid-19 vaccine. Let us tell you that Bharat Biotech has developed covaxin jointly with Indian Council of Medical Research. .
The company said in a statement, “The company plans to produce 200 million doses of covaxine per year at GMP facilities that are already operational for the production of vaccines based on inactive Vero Cell Platform technology.” Let us know that the product is expected to be available from the fourth quarter of the 2021 calendar year (October).
Earlier, the company had a capacity to manufacture 700 million doses of Covaxin a year at its facilities in Hyderabad and Bengaluru. This would mean that the total monthly capacity would be around 5.8 crore doses. However, the company is still in the process of increasing its production to reach this maximum capacity.
Bharat Krishna Biotech Chairman and Managing Director Dr Krishna Ella said during an interview to NDTV last month that the Hyderabad vaccine manufacturer managed to touch a capacity of 2 crore doses a month in April and to make around 30–35 million doses in May. Was expecting The additional facility of Bharat Biotech is expected to contribute to the government’s goal of increasing the dose of Kovid-19 vaccines available to the Indian population between August and December.
India has tied up with at least four manufacturers to increase the capacity of Bharat Biotech to produce the Kovid-19 vaccine. Hafkaine Biopharmaceutical Corporation of Maharashtra, Bharat Immunological and Biological Corporation of the Center, Indian Immunologicals Limited and OmniBRX Biotechnologies, Hester Biosciences and Gujarat Biotechnology Research Center will manufacture covaxin.
As a presentation on Tuesday by Minister of State for Chemicals and Fertilizers Mansukh L. Mandavia, as a result of the first three collaborations, the government expects covaxin production to increase to 135 million doses by November from 30 million doses in May. According to the presentation, with the addition of a consortium in Gujarat, Gujarat will get an additional 2 crore doses in 3-4 months.
According to Mandavia, the government has also received “in principle” consent from five German companies to manufacture kovaxine. He said that four other countries have also shown interest in the manufacture of this vaccine. However, international manufacture of indigenously developed vaccines will be permitted on the condition that at least half of the supplies produced will be sent to India.